Published on June 2, 2008 at 3:53 PM
DialysisPPO, a Pennsylvania Corporation providing cost containment solutions to the health plan market, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering its business method that enables health plans to significantly lower their exposure to the high cost of dialysis services while simultaneously improving the benefits to plan participants.
Plan members diagnosed with End-Stage Renal Disease ("ESRD") must either receive a kidney transplant or undergo a regular course of life-sustaining dialysis treatments.
Due to the gravity of this disease, ESRD is the only diagnosis in all of American healthcare that entitles a person to Medicare coverage, regardless of their age.
Unfortunately for health plans, Medicare does not become the primary payer for approximately three years, leaving health plans responsible for treatments that can cost in excess of $600,000 per person annually.
Our business method patent enables health plans to lower their annual costs by as much as 90%, while at the same time improving the level of benefits for plan members suffering from ESRD.
http://www.dialysisppo.com